SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:liu-155010"
 

Sökning: onr:"swepub:oai:DiVA.org:liu-155010" > Early tumor regrowt...

  • Heitz, F.Evangelische Huyssens Stiftung, Germany; Charite Univ Med Berlin, Germany; Free Univ Berlin, Germany; Humboldt Unive Berlin, Germany; Berlin Inst Hlth, Germany; AGO Study Grp, Germany (författare)

Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12

  • Artikel/kapitelEngelska2019

Förlag, utgivningsår, omfång ...

  • ACADEMIC PRESS INC ELSEVIER SCIENCE,2019
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:liu-155010
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-155010URI
  • https://doi.org/10.1016/j.ygyno.2018.11.008DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:140283869URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Objective. Surgical assessment of residual tumor provides the strongest prognostic information in advanced ovarian cancer (AOC), with the best outcome observed after complete resection. Postoperative radiological assessment before initiation of chemotherapy can supplement the information obtained by surgical assessment; however, it may also reveal conflicting findings. Methods. Patients with AOC enrolled in the AGO-OVAR 12 trial underwent baseline imaging before the first chemotherapy cycle. The findings from surgical and radiologic assessment for disease extend were compared. Additionally, an integrated approach was assessed. Results. Complete data from all 3 assessment methods were available for 1345 patients. Of 689 patients with complete resection, tumor was observed in 28% and 22% of patients undergoing radiologic and integrated assessment, respectively. Patients with surgical- radiological and surgical-integrated concordant findings showed a 5-year overall survival (5Y-OS) of 72% and 71%, whereas patients with surgical-radiological and surgical-integrated discordant results showed inferior 5Y-OS of 47% and 49%, respectively. Patients with surgically assessed residual disease had a 5-YOS of 37%. The interval between surgery and baseline assessment was independently associated with discordance between assessment methods, which might reflect early tumor regrowth. Conclusions. Baseline tumor assessment before chemotherapy provides information that stratifies patients with complete resection into different prognostic groups. Integrating the data from different assessment methods might lead to improved definitions of prognostic groups. Further investigation to determine if earlier initiation of chemotherapy after debulking surgery could increase survival of patients with early tumor regrowth is warranted. (C) 2018 Published by Elsevier Inc.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Harter, P.Evangelische Huyssens Stiftung, Germany; AGO Study Grp, Germany (författare)
  • Åvall-Lundqvist, Elisabeth,Professor,1957-Linköpings universitet,Avdelningen för Kirurgi, Ortopedi och Onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US,Karolinska Inst, Linkoping, Sweden; NSGO Study Grp, Germany(Swepub:liu)eliav51 (författare)
  • Reuss, A.Coordinating Ctr Clin Trials, Germany; AGO Study Grp, Germany (författare)
  • Pautier, P.Inst Gustave Roussy, France; GINECO Study Grp, Germany (författare)
  • Cormio, G.Univ Bari, Italy; Natl Canc Inst Giovanni Paolo II, Italy; MITO Study Grp, Germany (författare)
  • Colombo, N.Univ Milano Bicocca, Italy; Inst Europeo Oncol, Italy; MaNGO Study Grp, Germany (författare)
  • Reinthaller, A.Med Univ Vienna, Austria; AGO Austria Study Grp, Austria (författare)
  • Vergote, I.Univ Leuven, Belgium; BGOG Study Grp, Austria (författare)
  • Poveda, A.Inst Valenciano Oncol, Spain; GEICO Study Grp, Spain (författare)
  • Ottevanger, P. B.Radboud Univ Nijmegen, Netherlands; DGOG Study Grp, Spain (författare)
  • Hanker, L. C.Univ Schleswig Holstein, Germany; AGO Study Grp, Germany (författare)
  • Leminen, A.Womens Hosp Med Ctr, Finland; NSGO Study Grp, Germany (författare)
  • Alexandre, J.Hop Univ Paris Ctr, France; GINECO Study Grp, Germany (författare)
  • Canzler, U.Tech Univ Dresden, Germany; AGO Study Grp, Germany (författare)
  • Sehouli, J.Charite Campus Virchow Klinikum, Germany; AGO Study Grp, Germany (författare)
  • Herrstedt, J.Odense Univ Hosp, Denmark; Zealand Univ, Denmark; NSGO Study Grp, Germany (författare)
  • Fiane, B.Stavanger Univ Hosp, Norway; NSGO Study Grp, Germany (författare)
  • Merger, M.Boehringer Ingelheim Pharma GmbH and Co KG, Germany (författare)
  • du Bois, A.AGO Study Grp, Germany (författare)
  • Evangelische Huyssens Stiftung, Germany; Charite Univ Med Berlin, Germany; Free Univ Berlin, Germany; Humboldt Unive Berlin, Germany; Berlin Inst Hlth, Germany; AGO Study Grp, GermanyEvangelische Huyssens Stiftung, Germany; AGO Study Grp, Germany (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Gynecologic Oncology: ACADEMIC PRESS INC ELSEVIER SCIENCE152:2, s. 235-2420090-82581095-6859

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy